Reumatizam, Vol. 60 No. 1, 2013.
Stručni rad
Guidelines on biologic drugs for the treatment of children with juvenile idiopathic arthritis (JIA)
Lana Tambić Bukovac
; Reumatološki odjel, Dječja bolnica Srebrnjak, Zagreb, Hrvatska
Mandica Vidović
; Reumatološki odjel, Dječja bolnica Srebrnjak, Zagreb, Hrvatska
Lovro Lamot
; Reumatološki odjel, Dječja bolnica Srebrnjak, Zagreb, Hrvatska
Marija Perica
; Reumatološki odjel, Dječja bolnica Srebrnjak, Zagreb, Hrvatska
Miroslav Harjaček
; Reumatološki odjel, Dječja bolnica Srebrnjak, Zagreb, Hrvatska
Sažetak
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children, and one of the major causes of short-term or long-term disability, and impairment of quality of life in childhood. Without early and adequate treatment the disease will progress and result with irreparable joint damage. The choice of therapy depends on the JIA subtype, disease activity index, prognostic factors, and prooven efficacy and probable side-effects of the drugs. The goal of modern JIA therapy is the achievement of complete disease remission, and not only the improvement of symptoms and temporarily inflammation control. The implementation of biologics significantly altered therapeutic approach to children with resistant JIA. We present Croatian guidelines on biologic drugs for the treatment of patients with JIA.
Ključne riječi
juvenile idiopathic arthritis; biologic drugs
Hrčak ID:
123601
URI
Datum izdavanja:
1.6.2013.
Posjeta: 3.241 *